40 completed, 18 unknown, 9 terminated, 6 active not recruiting. 84 Phase 3, 11 Phase 2.
Follow Gemcitabine Hydrochloride: new trials by email Literature Review of Gemcitabine Hydrochloride trials Research Report on Gemcitabine Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer FG-M108, nab paclitaxel, Gemcitabine (GEM) - Pancreatic Cancer | Phase 3 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 524 | 2026-02-28 | 2026-02-04 |
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer Fluzoparib, Apatinib Mesylate, Capecitabine tablets - Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 200 | 2024-06-12 | 2025-08-15 |
| Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer Ascorbate, Nab paclitaxel, Gemcitabine - Metastatic Pancreatic Adenocarcinoma | Phase 3 | Unknown | Fudan University | 100 | 2023-08-20 | 2025-08-07 |
| Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study Toripalimab, Lenvatinib mesylate capsules, Placebo IV - Intrahepatic Cholangiocarcinoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 480 | 2023-06-19 | 2025-04-23 |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 131 | 2021-11-12 | 2026-10-28 |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 184 | 2021-06-28 | 2026-10-26 |
| Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy - Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8 | Phase 2 / Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 186 | 2021-02-24 | 2026-10-19 |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) Biospecimen Collection, Carboplatin, Cisplatin - Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1210 | 2020-06-16 | 2026-10-28 |
| Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma Tislelizumab, Placebo, Cisplatin - Urothelial Carcinoma | Phase 3 | Active not recruiting | BeiGene | 420 | 2019-05-29 | 2026-06-22 |
| Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer Capecitabine, Cisplatin, Gemcitabine - Stage I Gallbladder Cancer AJCC v8, Stage II Gallbladder Cancer AJCC v8 | Phase 3 | Withdrawn | Emory University | 2019-04-03 | 2020-06-05 | |
| Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel - Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8 | Phase 3 | Completed | SWOG Cancer Research Network | 452 | 2019-02-07 | 2026-01-12 |
| EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX EndoTAG-1, Gemcitabine - Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer | Phase 3 | Completed | SynCore Biotechnology Co., Ltd. | 218 | 2018-10-16 | 2023-05-06 |
| A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer EndoTAG-1, Paclitaxel, Gemcitabine Hydrochloride - Triple-Negative Breast Cancer | Phase 3 | Suspended | SynCore Biotechnology Co., Ltd. | 420 | 2016-11-23 | 2023-04-26 |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Biospecimen Collection, Carboplatin, Cediranib Maleate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 579 | 2016-03-28 | 2026-10-01 |
| Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy Volumetric Arc Radiotherapy, Interstitial brachytherapy, Cisplatin - Cervical Cancer | Phase 3 | Unknown | The National Center of Oncology, Azerbaijan | 400 | 2015-03-01 | 2016-11-15 |
| Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA Bone Scan, Cisplatin, Clinical Observation - EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7 | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 924 | 2014-07-01 | 2026-10-13 |
| Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Clinical Observation, Docetaxel, Doxorubicin Hydrochloride - Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma | Phase 3 | Terminated | Gynecologic Oncology Group | 38 | 2012-06-04 | 2020-04-28 |
| Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine - Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 546 | 2010-04-05 | 2026-02-23 |
| Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer carboplatin, celecoxib, gemcitabine hydrochloride - Lung Cancer | Phase 3 | Terminated | Alliance for Clinical Trials in Oncology | 313 | 2010-02-01 | 2018-07-23 |
Showing 20 of 84. Sign in to see all of them.
Pancreatic Neoplasms (24) · Carcinoma, Non-Small-Cell Lung (20) · Lung Neoplasms (19) · Gallbladder Neoplasms (7) · Urinary Bladder Neoplasms (7) · Adenocarcinoma of Lung (5) · Bile Duct Neoplasms (4) · Breast Neoplasms (4) · Ovarian Neoplasms (4) · Carcinoma, Transitional Cell (3) · Cholangiocarcinoma (3) · Liver Neoplasms (3) · Urethral Neoplasms (3) · Uterine Cervical Neoplasms (3) · Adenocarcinoma, Bronchiolo-Alveolar (2)
National Cancer Institute (NCI) (10) · European Organisation for Research and Treatment of Cancer - EORTC (6) · SWOG Cancer Research Network (4) · Alliance for Clinical Trials in Oncology (3) · Federation Francophone de Cancerologie Digestive (3) · GERCOR - Multidisciplinary Oncology Cooperative Group (3) · Gynecologic Oncology Group (3) · NCIC Clinical Trials Group (3) · Astex Pharmaceuticals, Inc. (2) · ECOG-ACRIN Cancer Research Group (2) · Istituto Nazionale per lo Studio e la Cura dei Tumori (2) · Pfizer (2) · Royal Liverpool University Hospital (2) · SynCore Biotechnology Co., Ltd. (2) · The Christie NHS Foundation Trust (2)
United States (44) · Canada (18) · France (16) · United Kingdom (15) · Belgium (9) · Italy (9) · China (7) · Germany (7) · Israel (7) · Australia (6) · Netherlands (6) · Hungary (4) · Japan (4) · Poland (4) · Puerto Rico (4)
Malcolm J. Moore, MD (3) · Pascal Hammel, MD, PhD (3) · Cesare Gridelli, MD (2) · Christophe Louvet, MD, PhD (2) · Lawrence A. Romel, MS (2) · Nick Thatcher, PhD, FRCP (2) · Adrian Hodson (1) · Al B. Benson, MD, FACP (1) · Andreas Boehle, MD (1) · Angel J. Lacave, MD, PhD (1) · Bradley Monk (1) · Bruno Chauffert (1) · Camillo F. Pollera, MD (1) · Christoph Zielinski, MD (1) · Cora Sternberg, Dr. (1)
PMID 37185961, PMID 12618501, PMID 12837810, PMID 14581415, PMID 15839957, PMID 15908661, PMID 16966687, PMID 16968876, PMID 16983112, PMID 17084621, PMID 17452677, PMID 17544497, PMID 18319412, PMID 18467316, PMID 18594318, PMID 18992248, PMID 19013107, PMID 19029412, PMID 19231158, PMID 19581537, PMID 19786668, PMID 19833819, PMID 19858379, PMID 20035187, PMID 20347506, PMID 20375404, PMID 20593535, PMID 20606093, PMID 20823433, PMID 20837948, PMID 20934270, PMID 20947887, PMID 21277694, PMID 21499862, PMID 21561347, PMID 21625252, PMID 22162575, PMID 22276821, PMID 22370319, PMID 22682806, PMID 22782416, PMID 23969788, PMID 24360787, PMID 24779680, PMID 25241229, PMID 25267740, PMID 25498218, PMID 25713428, PMID 26109202, PMID 26201606
U10CA027469 (5), U10CA180868 (5), U10CA180820 (4), U10CA032102 (3), U10CA021661 (2), U10CA031946 (2), U10CA180821 (2), U10CA180888 (2), 2005 (1), N02CM62212 (1), P30CA008748 (1), P30CA043703 (1), U10CA021115 (1), U10CA180830 (1)